137 | IBRUTINIB ADDED TO MCL TREATMENT HAS STRONG IMPACT ON MRD RESPONSE AND DISEASE KINETICS: RESULTS FROM THE TRIANGLE TRIALMouhamad Khouja, Christiane Pott, Ana Milena Herrera et al.|Hematological Oncology|2025Cited by 1
265 | IMPACT OF IGHV REPERTOIRE AFTER IBRUTINIB‐CONTAINING REGIMENS IN YOUNGER UNTREATED MCL PATIENTS: AN ANALYSIS OF THE TRIANGLE DATA EMBEDDED IN THE MULTIPLY PROJECTSimone Ragaini, Marco Ladetto, Christa Homburg et al.|Hematological Oncology|2025Cited by 1